ValuEngine Downgrades Recro Pharma (NASDAQ:REPH) to Hold

Share on StockTwits

ValuEngine downgraded shares of Recro Pharma (NASDAQ:REPH) from a buy rating to a hold rating in a research report report published on Monday, September 17th.

REPH has been the subject of a number of other reports. Roth Capital set a $9.00 price objective on Recro Pharma and gave the stock a buy rating in a research report on Saturday, May 26th. Zacks Investment Research raised Recro Pharma from a sell rating to a hold rating in a research report on Thursday, May 31st. BidaskClub raised Recro Pharma from a hold rating to a buy rating in a research report on Thursday, May 24th. Piper Jaffray Companies lowered their price objective on Recro Pharma from $17.00 to $9.00 and set an overweight rating for the company in a research report on Thursday, May 24th. Finally, Oppenheimer set a $18.00 price objective on Recro Pharma and gave the stock a buy rating in a research report on Friday, May 25th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Recro Pharma presently has a consensus rating of Buy and a consensus price target of $12.96.

NASDAQ REPH remained flat at $$6.66 during trading on Monday. The company’s stock had a trading volume of 170,757 shares, compared to its average volume of 263,535. The firm has a market cap of $147.30 million, a P/E ratio of -3.35 and a beta of -0.82. The company has a debt-to-equity ratio of 2.22, a quick ratio of 1.42 and a current ratio of 1.59. Recro Pharma has a 52 week low of $4.78 and a 52 week high of $13.05.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.72. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%. The company had revenue of $21.74 million during the quarter, compared to the consensus estimate of $16.81 million. On average, sell-side analysts anticipate that Recro Pharma will post -2.46 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. Northern Trust Corp lifted its stake in Recro Pharma by 28.0% during the second quarter. Northern Trust Corp now owns 220,965 shares of the specialty pharmaceutical company’s stock worth $1,109,000 after purchasing an additional 48,297 shares during the last quarter. Newtyn Management LLC purchased a new stake in Recro Pharma during the second quarter worth approximately $4,456,000. Orbimed Advisors LLC purchased a new stake in Recro Pharma during the second quarter worth approximately $539,000. Engine Capital Management LP lifted its stake in Recro Pharma by 472.3% during the second quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock worth $1,964,000 after purchasing an additional 322,937 shares during the last quarter. Finally, Alambic Investment Management L.P. lifted its stake in Recro Pharma by 378.0% during the second quarter. Alambic Investment Management L.P. now owns 47,990 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 37,950 shares during the last quarter. Hedge funds and other institutional investors own 55.86% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Recommended Story: Discount Rate

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.